Servier
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
FDA Approves Servier's Voranigo for Certain IDH-Mutated Gliomas
The approval marks the first targeted therapy commercially available for patients with grade 2 IDH-mutated glioma.
AmoyDx, Servier Partner to Develop CDx for Diffuse Glioma in China
The companies will develop a test to detect isocitrate dehydrogenase 1 and 2 gene mutations for use with Servier's investigational drug vorasidenib.
NICE Recommends Servier's Tibsovo With Chemo for Newly Diagnosed IDH1-Mutant AML
The institute estimated that around 130 AML patients with IDH1-mutated disease will be eligible for this treatment in England.
Servier Files for Vorasidenib Glioma Approvals in US, Europe
The firm is seeking approvals for vorasidenib in IDH1/2 mutated residual or recurrent grade 2 glioma based on the results of its Phase III INDIGO trial.
May 18, 2023